{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,9]],"date-time":"2026-10-09T16:26:41Z","timestamp":1791563201606,"version":"4.3.4"},"reference-count":31,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,6,6]],"date-time":"2026-06-06T00:00:00Z","timestamp":1780704000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2026,8,13]],"date-time":"2026-08-13T00:00:00Z","timestamp":1786579200000},"content-version":"vor","delay-in-days":68,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Transl Med"],"DOI":"10.1186\/s12967-026-08394-6","type":"journal-article","created":{"date-parts":[[2026,6,6]],"date-time":"2026-06-06T13:43:23Z","timestamp":1780753403000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Association of baseline immune cell composition with CAR-T cell expansion and survival in Relapsed\/Refractory large B-Cell lymphoma"],"prefix":"10.1186","volume":"24","author":[{"given":"Xin-di","family":"Liu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"He-nan","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Li-jie","family":"Zeng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuan-zheng","family":"Liang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fu-li","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jin-yan","family":"Zhu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jia","family":"Cong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6140-914X","authenticated-orcid":false,"given":"Liang","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,6,6]]},"reference":[{"issue":"26","key":"8394_CR1","doi-asserted-by":"publisher","first-page":"2531","DOI":"10.1056\/NEJMoa1707447","volume":"377","author":"SS Neelapu","year":"2017","unstructured":"Neelapu SS, Locke FL, Bartlett NL, Lekakis LJ, Miklos DB, Jacobson CA, et al. Axicabtagene ciloleucel CAR T-Cell therapy in refractory large B-Cell lymphoma. N Engl J Med. 2017;377(26):2531\u201344. https:\/\/doi.org\/10.1056\/NEJMoa1707447.","journal-title":"N Engl J Med"},{"issue":"1","key":"8394_CR2","doi-asserted-by":"publisher","first-page":"45","DOI":"10.1056\/NEJMoa1804980","volume":"380","author":"SJ Schuster","year":"2019","unstructured":"Schuster SJ, Bishop MR, Tam CS, Waller EK, Borchmann P, McGuirk JP, et al. Tisagenlecleucel in adult relapsed or refractory diffuse large B-Cell lymphoma. N Engl J Med. 2019;380(1):45\u201356. https:\/\/doi.org\/10.1056\/NEJMoa1804980.","journal-title":"N Engl J Med"},{"issue":"10254","key":"8394_CR3","doi-asserted-by":"publisher","first-page":"839","DOI":"10.1016\/S0140-6736(20)31366-0","volume":"396","author":"JS Abramson","year":"2020","unstructured":"Abramson JS, Palomba ML, Gordon LI, Lunning MA, Wang M, Arnason J, et al. Lisocabtagene maraleucel for patients with relapsed or refractory large B-cell lymphomas (TRANSCEND NHL 001): a multicentre seamless design study. Lancet. 2020;396(10254):839\u201352. https:\/\/doi.org\/10.1016\/S0140-6736(20)31366-0.","journal-title":"Lancet"},{"issue":"24","key":"8394_CR4","doi-asserted-by":"publisher","first-page":"3750","DOI":"10.1182\/blood-2014-01-552174","volume":"123","author":"Y Xu","year":"2014","unstructured":"Xu Y, Zhang M, Ramos CA, Durett A, Liu E, Dakhova O, et al. Closely related T-memory stem cells correlate with in vivo expansion of CAR.CD19-T cells and are preserved by IL-7 and IL-15. Blood. 2014;123(24):3750\u201359. https:\/\/doi.org\/10.1182\/blood-2014-01-552174.","journal-title":"Blood"},{"issue":"5","key":"8394_CR5","doi-asserted-by":"publisher","first-page":"1755","DOI":"10.1111\/trf.15287","volume":"59","author":"N Elavia","year":"2019","unstructured":"Elavia N, Panch SR, McManus A, Bikkani T, Szymanski J, Highfill SL, et al. Effects of starting cellular material composition on chimeric antigen receptor T-cell expansion and characteristics. Transfusion. 2019;59(5):1755\u201364. https:\/\/doi.org\/10.1111\/trf.15287.","journal-title":"Transfusion"},{"issue":"9","key":"8394_CR6","doi-asserted-by":"publisher","first-page":"869","DOI":"10.1016\/j.jcyt.2022.05.003","volume":"24","author":"M Qayed","year":"2022","unstructured":"Qayed M, McGuirk JP, Myers GD, Parameswaran V, Waller EK, Holman P, et al. Leukapheresis guidance and best practices for optimal chimeric antigen receptor T-cell manufacturing. Cytotherapy. 2022;24(9):869\u201378. https:\/\/doi.org\/10.1016\/j.jcyt.2022.05.003.","journal-title":"Cytotherapy"},{"key":"8394_CR7","doi-asserted-by":"publisher","unstructured":"Bai Z, Woodhouse S, Zhao Z, Arya R, Govek K, Kim D, et al. Single-cell antigen-specific landscape of CAR T infusion product identifies determinants of CD19-positive relapse in patients with ALL. Sci Adv. 2022;8(23):eabj2820. https:\/\/doi.org\/10.1126\/sciadv.abj2820.","DOI":"10.1126\/sciadv.abj2820"},{"issue":"5","key":"8394_CR8","doi-asserted-by":"publisher","first-page":"563","DOI":"10.1038\/s41591-018-0010-1","volume":"24","author":"JA Fraietta","year":"2018","unstructured":"Fraietta JA, Lacey SF, Orlando EJ, Pruteanu-Malinici I, Gohil M, Lundh S, et al. Determinants of response and resistance to CD19 chimeric antigen receptor (CAR) T cell therapy of chronic lymphocytic leukemia. Nat Med. 2018;24(5):563\u201371. https:\/\/doi.org\/10.1038\/s41591-018-0010-1.","journal-title":"Nat Med"},{"issue":"16_Supplement","key":"8394_CR9","doi-asserted-by":"publisher","first-page":"4236","DOI":"10.1158\/1538-7445.AM2020-4236","volume":"80","author":"GM Chen","year":"2020","unstructured":"Chen GM, Chen C, Das RK, Ding Y-Y, He B, Kim H, et al. Abstract 4236: a subtype-specific T-cell transcriptomic atlas reveals determinants of T-cell dysfunction in CAR T-cell therapy resistance. Cancer Res. 2020;80(16_Supplement):4236. https:\/\/doi.org\/10.1158\/1538-7445.AM2020-4236.","journal-title":"Cancer Res"},{"issue":"1","key":"8394_CR10","doi-asserted-by":"publisher","first-page":"213","DOI":"10.1038\/s41408-024-01193-6","volume":"14","author":"Z Tao","year":"2024","unstructured":"Tao Z, Chyra Z, Kotulov\u00e1 J, Celichowski P, Mih\u00e1lyov\u00e1 J, Charv\u00e1tov\u00e1 S, et al. Impact of T cell characteristics on CAR-T cell therapy in hematological malignancies. Blood Cancer J. 2024;14(1):213. https:\/\/doi.org\/10.1038\/s41408-024-01193-6.","journal-title":"Blood Cancer J"},{"key":"8394_CR11","doi-asserted-by":"publisher","first-page":"1431211","DOI":"10.3389\/fimmu.2024.1431211","volume":"15","author":"G Du","year":"2024","unstructured":"Du G, Dou C, Sun P, Wang S, Liu J, Ma L. Regulatory T cells and immune escape in HCC: understanding the tumor microenvironment and advancing CAR-T cell therapy. Front Immunol. 2024;15:1431211. https:\/\/doi.org\/10.3389\/fimmu.2024.1431211.","journal-title":"Front Immunol"},{"key":"8394_CR12","doi-asserted-by":"publisher","unstructured":"Ouyang W, Jin SW, Xu N, Liu W-Y, Zhao H, Zhang L, et al. PD-1 downregulation enhances CAR-T cell antitumor efficiency by preserving a cell memory phenotype and reducing exhaustion. J Immunother Cancer. 2024;12(4):e008429. https:\/\/doi.org\/10.1136\/jitc-2023-008429.","DOI":"10.1136\/jitc-2023-008429"},{"issue":"10","key":"8394_CR13","doi-asserted-by":"publisher","first-page":"6454","DOI":"10.21037\/tcr-2025-938","volume":"14","author":"J Zhao","year":"2025","unstructured":"Zhao J, Wu H, Sun Z, Cui Y, Liu N, Wang Y, et al. shRNA-based PD-1 suppression preserves memory phenotype and function of CD19-targeted CAR-T cell. Transl Cancer Res. 2025;14(10):6454\u201368. https:\/\/doi.org\/10.21037\/tcr-2025-938.","journal-title":"Transl Cancer Res"},{"key":"8394_CR14","doi-asserted-by":"publisher","first-page":"1187850","DOI":"10.3389\/fimmu.2023.1187850","volume":"14","author":"CJ Sailer","year":"2023","unstructured":"Sailer CJ, Hong Y, Dahal A, Ryan AT, Mir S, Gerber SA, et al. PD-1Hi CAR-T cells provide superior protection against solid tumors. Front Immunol. 2023;14:1187850. https:\/\/doi.org\/10.3389\/fimmu.2023.1187850.","journal-title":"Front Immunol"},{"issue":"1","key":"8394_CR15","doi-asserted-by":"publisher","first-page":"1247","DOI":"10.1186\/s12967-025-07281-w","volume":"23","author":"B Xue","year":"2025","unstructured":"Xue B, Zhou J, Chen X, Liu Y, Lu H, Zhu Z, et al. Sequential PD-1 inhibitors as consolidative therapy post-CD19 CART in relapsed\/refractory NHL: a propensity score matching cohort study. J Transl Med. 2025;23(1):1247. https:\/\/doi.org\/10.1186\/s12967-025-07281-w.","journal-title":"J Transl Med"},{"issue":"1","key":"8394_CR16","doi-asserted-by":"publisher","first-page":"348","DOI":"10.4049\/jimmunol.1601494","volume":"199","author":"M Schmueck-Henneresse","year":"2017","unstructured":"Schmueck-Henneresse M, Omer B, Shum T, Tashiro H, Mamonkin M, Lapteva N, et al. Comprehensive approach for identifying the T cell subset origin of CD3 and CD28 antibody\u2013activated chimeric antigen receptor\u2013modified T cells. J Immunol. 2017;199(1):348\u201362. https:\/\/doi.org\/10.4049\/jimmunol.1601494.","journal-title":"J Immunol"},{"key":"8394_CR17","doi-asserted-by":"publisher","unstructured":"Hoffmann JM, Schubert ML, Wang L, H\u00fcckelhoven A, Sellner L, Stock S, et al. Differences in expansion potential of naive chimeric antigen receptor T cells from healthy donors and untreated chronic lymphocytic leukemia patients. Front Immunol. 2018;8(1956). https:\/\/doi.org\/10.3389\/fimmu.2017.01956.","DOI":"10.3389\/fimmu.2017.01956"},{"issue":"19","key":"8394_CR18","doi-asserted-by":"publisher","first-page":"4898","DOI":"10.1182\/bloodadvances.2020002394","volume":"4","author":"FL Locke","year":"2020","unstructured":"Locke FL, Rossi JM, Neelapu SS, Jacobson CA, Miklos DB, Ghobadi A, et al. Tumor burden, inflammation, and product attributes determine outcomes of axicabtagene ciloleucel in large B-cell lymphoma. Blood Adv. 2020;4(19):4898\u2013911. https:\/\/doi.org\/10.1182\/bloodadvances.2020002394.","journal-title":"Blood Adv"},{"issue":"1","key":"8394_CR19","doi-asserted-by":"publisher","first-page":"409","DOI":"10.1038\/s41392-023-01659-2","volume":"8","author":"Y Wang","year":"2023","unstructured":"Wang Y, Tong C, Lu Y, Wu Z, Guo Y, Liu Y, et al. Characteristics of premanufacture CD8+T cells determine CAR-T efficacy in patients with diffuse large B-cell lymphoma. Sig Transduct Target Ther. 2023;8(1):409. https:\/\/doi.org\/10.1038\/s41392-023-01659-2.","journal-title":"Sig Transduct Target Ther"},{"issue":"1","key":"8394_CR20","doi-asserted-by":"publisher","first-page":"35","DOI":"10.1016\/j.ccell.2023.11.011","volume":"42","author":"S Kaczanowska","year":"2024","unstructured":"Kaczanowska S, Murty T, Alimadadi A, Contreras CF, Duault C, Subrahmanyam PB, et al. Immune determinants of CAR-T cell expansion in solid tumor patients receiving GD2 CAR-T cell therapy. Cancer Cell. 2024;42(1):35\u201351.e8. https:\/\/doi.org\/10.1016\/j.ccell.2023.11.011.","journal-title":"Cancer Cell"},{"issue":"1","key":"8394_CR21","doi-asserted-by":"publisher","first-page":"21","DOI":"10.1158\/2643-3230.BCD-23-0112","volume":"5","author":"S Filosto","year":"2024","unstructured":"Filosto S, Vardhanabhuti S, Canales MA, Poir\u00e9 X, Lekakis LJ, de Vos S, et al. Product attributes of CAR T-cell therapy differentially associate with efficacy and toxicity in second-line large B-cell lymphoma (ZUMA-7). Blood Cancer Discov. 2024;5(1):21\u201333. https:\/\/doi.org\/10.1158\/2643-3230.BCD-23-0112.","journal-title":"Blood Cancer Discov"},{"issue":"15","key":"8394_CR22","doi-asserted-by":"publisher","first-page":"4657","DOI":"10.1182\/bloodadvances.2022007057","volume":"6","author":"A Cuffel","year":"2022","unstructured":"Cuffel A, Allain V, Faivre L, Di Blasi R, Morin F, Vercellino L, et al. Real-world characteristics of T-cell apheresis and clinical response to tisagenlecleucel in B-cell lymphoma. Blood Adv. 2022;6(15):4657\u201360. https:\/\/doi.org\/10.1182\/bloodadvances.2022007057.","journal-title":"Blood Adv"},{"key":"8394_CR23","doi-asserted-by":"publisher","unstructured":"Meyran D, Zhu J, Butler J, et al. 126 early-phenotype lewis Y CAR-T cells persist better in vivo and induce solid tumor regression in combination with anti-PD1. J Immunother Cancer. 2020;8(Suppl 3). https:\/\/doi.org\/10.1136\/jitc-2020-SITC2020.0126.","DOI":"10.1136\/jitc-2020-SITC2020.0126"},{"key":"8394_CR24","doi-asserted-by":"publisher","unstructured":"Ruggeri Barbaro N, Drashansky T, Tess K, Djedaini M, Hariri R, He S, et al. Placental circulating T cells: a novel, allogeneic CAR-T cell platform with preserved T-cell stemness, more favorable cytokine profile, and durable efficacy compared to adult PBMC-derived CAR-T. J Immunother Cancer. 2024;12(4):e008656. https:\/\/doi.org\/10.1136\/jitc-2023-008656.","DOI":"10.1136\/jitc-2023-008656"},{"issue":"11","key":"8394_CR25","doi-asserted-by":"publisher","first-page":"101803","DOI":"10.1016\/j.xcrm.2024.101803","volume":"5","author":"M Guerrero-Murillo","year":"2024","unstructured":"Guerrero-Murillo M, Rill-Hinarejos A, Trincado JL, Bataller A, Ortiz-Maldonado V, Ben\u00edtez-Ribas D, et al. Integrative single-cell multi-omics of CD19-CARpos and CARneg T cells suggest drivers of immunotherapy response in B cell neoplasias. Cell Rep. Med. 2024;5(11):101803. https:\/\/doi.org\/10.1016\/j.xcrm.2024.101803.","journal-title":"Cell Rep. Med"},{"key":"8394_CR26","doi-asserted-by":"publisher","unstructured":"Stock S, B\u00fccklein VL, Blumenberg V, Magno G, Emhardt A-J, Holzem AME, et al. Prognostic significance of immune reconstitution following CD19 CAR T-cell therapy for relapsed\/refractory B-cell lymphoma. Hemasphere. 2025;9(1):e70062. https:\/\/doi.org\/10.1002\/hem3.70062.","DOI":"10.1002\/hem3.70062"},{"issue":"1","key":"8394_CR27","doi-asserted-by":"publisher","first-page":"6","DOI":"10.1016\/j.cell.2025.11.035","volume":"189","author":"C Zou","year":"2026","unstructured":"Zou C, Li P, Li B, Sparwasser T, Yuan J. Next steps in regulatory T cells: biology and clinical application. Cell. 2026;189(1):6\u201322. https:\/\/doi.org\/10.1016\/j.cell.2025.11.035.","journal-title":"Cell"},{"issue":"1","key":"8394_CR28","doi-asserted-by":"publisher","first-page":"69","DOI":"10.1186\/s40164-024-00536-0","volume":"13","author":"D Zhou","year":"2024","unstructured":"Zhou D, Zhu X, Xiao Y. CAR-T cell combination therapies in hematologic malignancies. Exp Hematol Oncol. 2024;13(1):69. https:\/\/doi.org\/10.1186\/s40164-024-00536-0.","journal-title":"Exp Hematol Oncol"},{"key":"8394_CR29","doi-asserted-by":"publisher","unstructured":"Kegler A, Koristka S, Bergmann R, Berndt N, Arndt C, Feldmann A, et al. T cells engrafted with a UniCAR 28\/z outperform UniCAR BB\/z-transduced T cells in the face of regulatory T cell-mediated immunosuppression. Oncoimmunology. 2019;8(9):e1621676. https:\/\/doi.org\/10.1080\/2162402X.2019.1621676.","DOI":"10.1080\/2162402X.2019.1621676"},{"issue":"8","key":"8394_CR30","doi-asserted-by":"publisher","first-page":"2304","DOI":"10.1016\/j.ymthe.2023.07.007","volume":"31","author":"T Luetkens","year":"2023","unstructured":"Luetkens T. Bypassing the cytokine sink: IL-2-independent IL-2 receptor signaling. Mol Ther. 2023;31(8):2304\u201306. https:\/\/doi.org\/10.1016\/j.ymthe.2023.07.007.","journal-title":"Mol Ther"},{"issue":"1","key":"8394_CR31","doi-asserted-by":"publisher","first-page":"105","DOI":"10.1186\/s12967-024-06028-3","volume":"23","author":"R Zhang","year":"2025","unstructured":"Zhang R, Zhang Y, Xiao H, Liu Q, Zhao M. Knockout IL4I1 affects macrophages to improve poor efficacy of CD19 CAR-T combined with PD-1 inhibitor in relapsed\/refractory diffuse large B-cell lymphoma. J Transl Med. 2025;23(1):105. https:\/\/doi.org\/10.1186\/s12967-024-06028-3.","journal-title":"J Transl Med"}],"container-title":["Journal of Translational Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12967-026-08394-6","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12967-026-08394-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12967-026-08394-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,12]],"date-time":"2026-08-12T23:50:58Z","timestamp":1786578658000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1186\/s12967-026-08394-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6,6]]},"references-count":31,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["8394"],"URL":"https:\/\/doi.org\/10.1186\/s12967-026-08394-6","relation":{},"ISSN":["1479-5876"],"issn-type":[{"value":"1479-5876","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,6,6]]},"assertion":[{"value":"10 April 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"29 May 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"6 June 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"This study received approval from the Ethics Committee of Beijing Tongren Hospital, Capital Medical University (approval number: TREC2025-KY207). It adhered to the Helsinki Declaration\u2019s ethical guidelines. All patients provided written informed consent.","order":1,"name":"Ethics","label":"Ethics approval","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Consent obtained directly from patients.","order":2,"name":"Ethics","label":"Patient consent for publication","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not commissioned; externally peer reviewed.","order":3,"name":"Ethics","label":"Provenance and peer review","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"None declared.","order":4,"name":"Ethics","label":"Competing interests","group":{"name":"EthicsHeading","label":"Declarations"}}],"article-number":"1041"}}